Vnitr Lek 2015, 61(5):458-465

Combination treatment of hypertension in 2015

Jindřich ©pinar1,*, Jiří Vítovec2, Lenka ©pinarová2, Miroslava Bendová3
1 Interní kardiologická klinika LF MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
2 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka ©pinarová, CSc., FESC
3 Nemocniční lékárna FN Brno, pracoviątě Bohunice, vedoucí PharmDr. Tatiana Holubová

We present an overview of the present views on combination treatment and on fixed combinations in the treatment of hypertension according to guidelines of ESH/ESC and ČSH from 2013. The most frequently recommended dual combinations include a blocker of the renin-angiotensin system (ACEI or sartan) and a calcium channel blocker, and further a blocker of the renin-angiotensin system and a diuretic and a calcium channel blocker and a diuretic. In 2014 a fixed-dose combination of an ACE inhibitor (perindopril), a calcium channel blocker (amlodipine) and an diuretic (indapamide) appeared on the Czech market. Within the PIANIST study including 4 731 insufficiently controlled hypertensives, a fixed-dose triple combination of perindopril, amlodipine and indapamide led to a decrease in blood pressure by 28.3/13.8 mm Hg and to a sufficient control of hypertension in 92 % of patients. The advantage of fixed combinations primarily consists in greater compliance of patients and thereby in a better control of hypertension. About 1/3 of hypertensives need a triple combination for a satisfactory blood pressure control.

Keywords: fixed-dose combination; hypertension; triple combination

Received: February 17, 2015; Accepted: April 8, 2015; Published: May 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J, ©pinarová L, Bendová M. Combination treatment of hypertension in 2015. Vnitr Lek. 2015;61(5):458-465.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Filipovský J, Widimský J jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze, verze 2012: Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-801. Go to PubMed...
    2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertension 2013; 31(7): 1281-1357. Go to original source... Go to PubMed...
    3. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289(18): 2363-2369. Go to original source... Go to PubMed...
    4. Cífková R, ©kodová Z, Bruthans J et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28(11): 2196-2203. Go to original source... Go to PubMed...
    5. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Medicine 2009; 122(3): 290-300. Go to original source... Go to PubMed...
    6. Dahlöf B, Sever PS, Poulter NR. ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Go to original source... Go to PubMed...
    7. Bramlage P, Bohm M, Volpe M et al. A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patiens. J Clin Hypertens (Greenwich) 2010; 12(9): 666-677. Go to original source... Go to PubMed...
    8. Kettani FZ, Dragomir A, Côté R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40(1): 213-220. Go to original source... Go to PubMed...
    9. Peters R, Beckett N, Forrete F et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7(8): 683-689. Go to original source... Go to PubMed...
    10. Mancia G, Laurent S, Agabiti-Rosei L et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009; 27(11): 2121-2158. Go to original source... Go to PubMed...
    11. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713-719. Go to original source... Go to PubMed...
    12. Vítovec J, ©pinar J. Kombinační léčba hypertenze s přihlédnutím k fixním kombinacím. Kardiol Rev Int Med 2014; 16(6): 444-446.
    13. ©pinar J, Vítovec J Kombinační léčba hypertenze. Causa Subita 2012; 15(1): 10-13.
    14. Souček M, Řiháček I, P. Fráňa et al. Léčba hypertenze v rámci metabolického syndromu. Kardiol Rev Int Med 2010; 12(2): 73-76.
    15. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2225. Go to original source... Go to PubMed...
    16. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21(4): 597-603. Go to original source... Go to PubMed...
    17. Tobe S, Kawecka-Jaszcz K, Zannad F et al. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J Clin Hypertens (Greenwich) 2007; 9(2): 120-127. Go to original source... Go to PubMed...
    18. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Go to original source... Go to PubMed...
    19. Poulter NR, Wedel H, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366(9489): 907-913. Go to original source... Go to PubMed...
    20. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417-2428. Go to original source... Go to PubMed...
    21. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375(9721): 1173-1181. Go to original source... Go to PubMed...
    22. Vítovec J, ©pinar J. Perindopril/indapamid - fixní kombinace. Remedia 2007; 17(3): 247-257.
    23. Vark LC, Bertrand M, Akkenthuis KM et al: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2011; 33(16): 2088-2097. Go to original source... Go to PubMed...
    24. Patel A. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840. Go to original source... Go to PubMed...
    25. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002; 4(5): 343-349. Go to original source... Go to PubMed...
    26. ©pinar J, Vítovec J. Kombinační léčba hypertenze. Causa Subita 2012; 15(1): 10-13.
    27. Hess G, Hill J, Lau H et al. Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose to Free-Combination Antihypertensive Therapy. P T 2008; 33(11): 652-666.
    28. James PA, Oparil S, Carter BL et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-520. Go to original source... Go to PubMed...
    29. Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009; 9(6): 411-418. Go to original source... Go to PubMed...
    30. Widimský J jr. První fixní trojkombinace perindopril arginin-indapamid-amlodipin: nový přístup v kombinační léčbě hypertenze. Vnitř Lék 2014; 60(9): 801-807. Go to PubMed...
    31. Widimský J jr. Trojkombinace v léčbě hypertenze. Kardiol Rev Int Med 2014; 16(6): 449-453.
    32. Widimský J Jr. Na český trh přichází vůbec první fixní antihypertenzní trojkombinace. Practicus 2014; 13(8): 29.
    33. Toth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients. Am J Cardiovasc Drugs 2014; 14(2): 137-145. Erratum in Am J Cardiovasc Drug. 2014; 14(3): 239. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.